Ovarian Cancer: Even Patients with New Infection benefit from Olaparib

被引:0
|
作者
Lichert, Frank
机构
关键词
D O I
暂无
中图分类号
R71 [妇产科学];
学科分类号
100211 ;
摘要
引用
收藏
页码:322 / 323
页数:2
相关论文
共 50 条
  • [1] No survival benefit of olaparib in ovarian cancer patients
    Bennet, Neil
    LANCET ONCOLOGY, 2012, 13 (05): : E192 - E192
  • [2] Olaparib, a new hope for ovarian cancer
    Samoon, Zarka
    Jabbar, Adnan Abdul
    INDIAN JOURNAL OF CANCER, 2020, 57 (03) : 346 - 347
  • [3] Olaparib recommendations for ovarian cancer patients
    Johnson, Peter
    FUTURE ONCOLOGY, 2016, 12 (02) : 149 - 151
  • [5] Experience with the use of olaparib in patients with ovarian cancer
    Gallardo-Rincon, Dolores
    Alamilla-Garcia, Gabriela
    Montes-Servin, Edgar
    Morales-Vazquez, Flavia
    Cano-Blanco, Claudia
    Coronel-Martinez, Jaime
    Bahena-Gonzalez, Antonio
    Gerson-Cwilich, Raquel
    Isla-Ortiz, David
    Toledo-Leyva, Alfredo
    Montes-Servin, Elizabeth
    Michel-Tello, David
    Espinosa-Romero, Raquel
    GACETA MEDICA DE MEXICO, 2019, 155 (06): : 585 - 589
  • [6] COMPARATIVE BENEFIT OF OLAPARIB IN RECURRENT BRCAM OVARIAN, BREAST, PANCREATIC AND PROSTATE CANCER
    Peters, P.
    Manrriquez, E.
    Amanam, I.
    Chan, J.
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2020, 30 : A47 - A47
  • [7] New Biologic Frontiers in Ovarian Cancer: Olaparib Update
    Previs, Rebecca A.
    Dalton, Heather J.
    Coleman, Robert L.
    AMERICAN JOURNAL OF HEMATOLOGY-ONCOLOGY, 2016, 12 (11) : 14 - 22
  • [8] Pancreatic cancer patients with germline BRCA mutations can benefit from olaparib treatment
    Mukherjee, Shibani
    Asaithamby, Aroumougame
    TRANSLATIONAL CANCER RESEARCH, 2020, 9 (04) : 2154 - 2156
  • [9] Olaparib for the treatment of ovarian cancer
    Lheureux, Stephanie
    Oza, Amit M.
    EXPERT OPINION ON ORPHAN DRUGS, 2014, 2 (05): : 497 - 508
  • [10] Olaparib in the treatment of ovarian cancer
    Washington, Christina R.
    Richardson, Debra L.
    Moore, Kathleen N.
    FUTURE ONCOLOGY, 2019, 15 (30) : 3435 - 3449